肝细胞癌患者接受阿替利珠单抗联合贝伐珠单抗治疗前FDG PET/CT体积参数的预后意义
该回顾性研究纳入78例接受阿替利珠单抗联合贝伐珠单抗治疗的肝细胞癌患者,于治疗前行FDG PET/CT测量肝内靶病灶的SUVmax、肿瘤/正常肝摄取比、代谢肿瘤体积和总病灶糖酵解(TLG)及肝外转移灶SUVmax。结果显示肝内病灶TLG独立预测无进展生存期(P=0.019)和总生存期(P=0.003),且与治疗反应显著相关。
要点
- 肝内病灶TLG独立预测PFS(P=0.019)和OS(P=0.003)。
- 代谢肿瘤体积仅与OS显著相关(P=0.010),肝外SUVmax仅与PFS显著相关(P=0.045)。
- 疾病进展患者的TLG显著高于完全或部分缓解者(P<0.05)。
核心结论
- 肝内HCC病灶的TLG与治疗反应显著相关,且为PFS和OS的独立预后因素。
- TLG可能作为预测接受阿替利珠单抗联合贝伐珠单抗治疗的HCC患者临床结局的影像生物标志物。
研究设计与样本
- 回顾性纳入78例接受阿替利珠单抗联合贝伐珠单抗治疗前行FDG PET/CT的肝细胞癌患者。
- 于治疗前影像学检查中确定肝内靶肿瘤病灶,并从PET/CT图像测量肝内病灶的SUVmax、肿瘤/正常肝摄取比、代谢肿瘤体积和总病灶糖酵解(TLG),以及肝外转移灶的SUVmax(肝外SUVmax)。
主要发现
- 疾病进展患者的TLG值显著高于达到完全或部分缓解的患者(P<0.05)。
- 多因素生存分析中,TLG独立预测PFS(P=0.019)和OS(P=0.003)。
- 代谢肿瘤体积仅与OS显著相关(P=0.010),肝外SUVmax仅与PFS显著相关(P=0.045)。
- 高TLG值患者的PFS和OS均差于低TLG值患者(P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to assess prognostic significance of FDG PET/CT parameters in predicting progression-free survival (PFS) and overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab therapy. PATIENTS AND METHODS: We retrospectively enrolled 78 patients with HCC who underwent FDG PET/CT before atezolizumab plus bevacizumab therapy and identified intrahepatic target tumor lesions on pretreatment imaging studies. From PET/CT images, we measured SUVmax, tumor-to-normal liver uptake ratio, metabolic tumor volume, and total lesion glycolysis (TLG) for intrahepatic tumor lesions, as well as SUVmax for extrahepatic metastatic lesions (extrahepatic SUVmax). RESULTS: In comparisons of PET/CT parameters, patients with progressive disease demonstrated significantly higher TLG values than those achieving complete or partial response ( P < 0.05). In the multivariate survival analysis, TLG independently predicted both PFS ( P = 0.019) and OS ( P = 0.003). Metabolic tumor volume was significantly associated with OS alone ( P = 0.010), and extrahepatic SUVmax was significantly associated with only PFS ( P = 0.045). Patients with high TLG values experienced poorer PFS and OS than those with low TLG values ( P < 0.05). CONCLUSIONS: TLG in intrahepatic HCC lesions was significantly associated with treatment response and served as an independent prognostic factor for PFS and OS. TLG could be a potential imaging biomarker for predicting clinical outcomes in patients with HCC receiving atezolizumab plus bevacizumab therapy.
引用
- Lee JW, Lee SM, Kang B, et al. Prognostic Significance of Volumetric Parameters on Pretreatment FDG PET/CT in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Therapy. Clin Nucl Med. 2025. PMID: 40254801. doi:10.1097/RLU.0000000000005896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。